Burkitt Lymphoma — Trials

Burkitt Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

247 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 27
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04094766	Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia	withdrawn	Phase 1	0	Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER	1	Nov 5, 2020	clinicaltrials
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	withdrawn	Phase 1 / Phase 2	0	Masonic Cancer Center, University of MinnesotaOTHER	1	Dec 2, 2017